All Analytical Techniques articles
-
News10x Genomics launches Atera whole-transcriptome spatial biology platform
The new platform enables researchers to analyse gene expression and cellular organisation within intact tissue at single-cell resolution, supporting large-scale studies across fresh-frozen and FFPE samples. Early adopters include leading research institutions and global service providers, with cloud-based analysis tools and direct sample processing services now available.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
ArticleAnalytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
WebinarFrom expert task to lab routine - Membrane protein purification and analysis simplified
A new way to tackle the most challenging drug targets: Discover a fully automated, detergent-free purification workflow that isolates membrane proteins in their native 3D structure in as little as three hours and with minimal hands-on time. Learn how to perform subsequent digital miniaturization and qPCR-based stability analysis with compact solutions that integrate seamlessly into your lab.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
InterviewComputational design drives new generation of synthetic promoters
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
-
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
-
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
-
InterviewFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.
-
NewsProbiotic bacteria successfully attacks tumours in preclinical models
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
-
NewsSonoPIN ultrasound method shows promise for targeted cancer therapy
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.
-
NewsNew target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
-
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
-
NewsNew AI tool could accelerate drug discovery and cut lab costs
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
-
NewsBlocking FAK protein may help to overcome resistance in ovarian cancer
A new preclinical study has demonstrated that locking the focal adhesion kinase (FAK) protein may help the immune system better detect and attack ovarian tumours.
-
InterviewHow self-driving labs are changing drug development
Automation and artificial intelligence are changing how scientists design, test and refine new molecules. At the University of Toronto, Stuart R Green and the Acceleration Consortium are building a self-driving lab that could change the pace of early drug discovery.
-
ArticleInternational Women’s Day: digital pathology in early drug discovery
For International Women’s Day, Dr Amanda Hemmerich, Global Director of Digital Pathology & Innovation at IQVIA Laboratories, describes how digital pathology is being applied in early drug development and what it takes to build credibility in a multidisciplinary technical field.
-
NewsGut drug boosts liver health in mice after small bowel surgery
Researchers at Washington University have developed a gut-specific drug that protects the liver and improves nutrient absorption in mice after small bowel surgery.
-
ArticleWhy most labs are not ready for AI: Cenevo shares what must change
Most labs want to use AI, but few have the digital foundations to support it. Cenevo’s leaders explain why progress is slow and what laboratories must fix before AI can deliver real value.